Table 3:

Characteristics of participants with a positive rapid antigen test

Age	Gender	Underlying comorbidity	Vaccine brand			Days from			Symp- toms	RBD prior to 3rd dose
			1st dose	2nd dose	3rd dose	1st to 2nd dose	2nd to 3rd dose	Last dose* to positive RAT
33	F	None	BNT162b2	mRNA1273	mRNA1273	42	190	25	Yes	1.73
33	M	None	mRNA1273	mRNA1273	N/A	28	N/A	204	Yes	N/A
36	F	Transplant	BNT162b2	mRNA1273	mRNA1273	63	190	33	Yes	1.44
38	M	Asthma	BNT162b2	BNT162b2	N/A	77	N/A	213	Yes	N/A
43	F	Asthma, chronic neurologic disease	AstraZeneca	mRNA1273	mRNA1273	66	186	50	Yes	1.08
44	F	None	mRNA1273	mRNA1273	mRNA1273	65	180	46	Yes	1.19
44	F	Asthma	BNT162b2	BNT162b2	mRNA1273	60	192	85	Yes	0.77
44	M	Asthma	BNT162b2	BNT162b2	N/A	50	N/A	277	Yes	1.05
45	F	None	BNT162b2	BNT162b2	mRNA1273	35	201	45	Yes	N/A
45	F	None	AstraZeneca	mRNA1273	mRNA1273	61	183	57	Yes	0.95
45	F	None	BNT162b2	BNT162b2	N/A	52	N/A	273	Yes	N/A
46	F	None	BNT162b2	BNT162b2	BNT162b2	83	215	18	Yes	1.12
47	M	None	AstraZeneca	mRNA1273	mRNA1273	61	183	55	Yes	1.56
48	M	None	AstraZeneca	AstraZeneca	BNT162b2	57	170	100	Yes	N/A
49	F	Hypertension	BNT162b2	mRNA1273	N/A	40	N/A	199	Yes	1.29
71	F	Diabetes	BNT162b2	BNT162b2	mRNA1273	96	163	48	Yes	N/A
73	F	None	BNT162b2	BNT162b2	BNT162b2	83	213	27	N/A	0.62
73	F	None	BNT162b2	BNT162b2	BNT162b2	73	179	75	Yes	0.49
73	F	None	BNT162b2	BNT162b2	BNT162b2	90	176	110	Yes	1.75
75	M	Hypertension	BNT162b2	BNT162b2	BNT162b2	80	217	6	Yes	0.79
76	M	Hypertension, stroke	BNT162b2	mRNA1273	BNT162b2	89	197	26	No 1.31
76	M	Hypertension, asthma, cancer	BNT162b2	mRNA1273	mRNA1273	88	182	68	Yes	0.49
76	F	None	BNT162b2	BNT162b2	mRNA1273	73	187	91	Yes	1.15
80	BNT162b2	BNT162b2	83	187	73	Yes	0.81
83	F	Hypertension	BNT162b2	mRNA1273	mRNA1273	49	203	25	No	1.36

* The 3rd dose if available or the 2nd dose if a participant did not receive a 3rd dose

M = Male; F= Female; RAT = Rapid antigen test; RBD = Normalized ratio of IgG antibody to the receptor binding domain